O	O	0	4	Cell	Cell	B-NP	NN	O	7	SUB	O
O	O	4	5	-	-	B-ADJP	HYPH	O	1	P	O
O	O	5	7	to	to	B-PP	TO	O	1	NMOD	O
O	O	7	8	-	-	B-NP	HYPH	O	6	NMOD	O
O	O	8	12	cell	cell	I-NP	NN	O	6	NMOD	O
O	O	13	20	contact	contact	I-NP	NN	O	3	PMOD	O
O	O	21	30	activates	activate	B-VP	VBZ	O	0	ROOT	O
O	O	31	34	the	the	B-NP	DT	O	11	NMOD	O
T4	B-Entity	35	39	long	long	I-NP	JJ	B-DNA	11	NMOD	B-DNA
T4	I-Entity	40	48	terminal	terminal	I-NP	JJ	I-DNA	11	NMOD	I-DNA
T4	I-Entity	49	55	repeat	repeat	I-NP	NN	I-DNA	7	OBJ	I-DNA
O	O	56	58	of	of	B-PP	IN	O	11	NMOD	O
O	O	59	64	human	human	B-NP	JJ	O	15	NMOD	O
O	O	65	81	immunodeficiency	immunodeficiency	I-NP	NN	O	15	NMOD	O
O	O	82	87	virus	virus	I-NP	NN	O	12	PMOD	O
O	O	88	89	1	1	I-NP	CD	O	15	NMOD	O
O	O	90	97	through	through	B-PP	IN	O	7	VMOD	O
O	O	98	101	its	its	B-NP	PRP$	O	20	NMOD	O
T5	B-Entity	102	108	kappaB	kappaB	I-NP	NN	B-DNA	20	NMOD	B-DNA
T5	I-Entity	109	114	motif	motif	I-NP	NN	I-DNA	17	PMOD	I-DNA
O	O	114	115	.	.	O	.	O	7	P	O

O	O	117	121	Cell	Cell	B-NP	NN	O	19	SUB	O
O	O	121	122	-	-	B-ADJP	HYPH	O	1	P	O
O	O	122	124	to	to	B-PP	TO	O	1	NMOD	O
O	O	124	125	-	-	B-NP	HYPH	O	6	NMOD	O
O	O	125	129	cell	cell	I-NP	NN	O	6	NMOD	O
O	O	130	137	contact	contact	I-NP	NN	O	3	PMOD	O
O	O	138	145	between	between	B-PP	IN	O	6	NMOD	O
O	O	146	156	peripheral	peripheral	B-NP	JJ	B-cell_type	10	NMOD	B-cell_type
O	O	157	162	blood	blood	I-NP	NN	I-cell_type	10	NMOD	I-cell_type
O	O	163	174	lymphocytes	lymphocyte	I-NP	NNS	I-cell_type	18	NMOD	I-cell_type
O	O	175	178	and	and	O	CC	O	18	NMOD	O
O	O	179	190	transfected	transfecte	B-VP	VBN	B-cell_line	18	NMOD	B-cell_line
O	O	191	196	human	human	B-NP	JJ	I-cell_line	18	NMOD	I-cell_line
O	O	197	204	colonic	colonic	I-NP	JJ	I-cell_line	18	NMOD	I-cell_line
O	O	205	214	carcinoma	carcinoma	I-NP	NN	I-cell_line	18	NMOD	I-cell_line
O	O	215	219	cell	cell	I-NP	NN	I-cell_line	18	NMOD	I-cell_line
O	O	220	224	line	line	I-NP	NN	I-cell_line	18	NMOD	I-cell_line
O	O	225	229	HT29	HT29	I-NP	NN	I-cell_line	7	PMOD	I-cell_line
O	O	230	239	activates	activate	B-VP	VBZ	O	0	ROOT	O
O	O	240	253	transcription	transcription	B-NP	NN	O	19	OBJ	O
O	O	254	256	of	of	B-PP	IN	O	20	NMOD	O
O	O	257	260	the	the	B-NP	DT	O	25	NMOD	O
T6	B-Entity	261	265	long	long	I-NP	JJ	B-DNA	25	NMOD	B-DNA
T6	I-Entity	266	274	terminal	terminal	I-NP	JJ	I-DNA	25	NMOD	I-DNA
T6	I-Entity	275	282	repeats	repeat	I-NP	NNS	I-DNA	21	PMOD	I-DNA
O	O	283	284	(	(	O	(	O	28	DEP	O
T7	B-Entity	284	287	LTR	LTR	B-NP	NN	B-DNA	28	DEP	B-DNA
O	O	287	288	)	)	O	)	O	25	NMOD	O
O	O	289	291	of	of	B-PP	IN	O	25	NMOD	O
O	O	292	297	human	human	B-NP	JJ	O	32	NMOD	O
O	O	298	314	immunodeficiency	immunodeficiency	I-NP	NN	O	32	NMOD	O
O	O	315	320	virus	virus	I-NP	NN	O	29	PMOD	O
O	O	320	321	.	.	O	.	O	19	P	O

T8	B-Entity	322	325	HIV	HIV	B-NP	NN	B-DNA	5	NMOD	B-DNA
T8	I-Entity	325	326	-	-	B-NP	HYPH	I-DNA	5	NMOD	I-DNA
T8	I-Entity	326	327	1	1	I-NP	CD	I-DNA	4	AMOD	I-DNA
T8	I-Entity	328	331	LTR	LTR	I-NP	NN	I-DNA	5	NMOD	I-DNA
O	O	332	345	transcription	transcription	I-NP	NN	O	6	SUB	O
O	O	346	348	is	be	B-VP	VBZ	O	0	ROOT	O
O	O	349	359	controlled	control	I-VP	VBN	O	6	VC	O
O	O	360	362	by	by	B-PP	IN	O	7	VMOD	O
O	O	363	364	a	a	B-NP	DT	O	11	NMOD	O
O	O	365	372	complex	complex	I-NP	JJ	O	11	NMOD	O
O	O	373	378	array	array	I-NP	NN	O	8	PMOD	O
O	O	379	381	of	of	B-PP	IN	O	11	NMOD	O
O	O	382	387	virus	virus	B-NP	NN	O	18	NMOD	O
O	O	387	388	-	-	O	HYPH	O	18	P	O
O	O	388	395	encoded	encode	B-NP	VBN	O	18	NMOD	O
O	O	396	399	and	and	I-NP	CC	O	18	NMOD	O
O	O	400	408	cellular	cellular	I-NP	JJ	B-protein	18	NMOD	B-protein
O	O	409	417	proteins	protein	I-NP	NNS	I-protein	12	PMOD	I-protein
O	O	417	418	.	.	O	.	O	6	P	O

O	O	419	424	Using	Use	B-VP	VBG	O	26	VMOD	O
O	O	425	432	various	various	B-NP	JJ	O	3	NMOD	O
O	O	433	443	constructs	construct	I-NP	NNS	O	1	OBJ	O
O	O	444	454	expressing	express	B-VP	VBG	O	3	NMOD	O
O	O	455	456	a	a	B-NP	DT	O	8	NMOD	O
T9	B-Entity	457	461	lacZ	lacZ	I-NP	NN	B-DNA	8	NMOD	B-DNA
T9	I-Entity	462	470	reporter	reporter	I-NP	NN	I-DNA	8	NMOD	I-DNA
T9	I-Entity	471	475	gene	gene	I-NP	NN	I-DNA	4	OBJ	I-DNA
O	O	476	481	under	under	B-PP	IN	O	4	VMOD	O
O	O	482	485	the	the	B-NP	DT	O	11	NMOD	O
O	O	486	493	control	control	I-NP	NN	O	9	PMOD	O
O	O	494	496	of	of	B-PP	IN	O	11	NMOD	O
O	O	497	500	the	the	B-NP	DT	O	14	NMOD	O
O	O	501	507	intact	intact	I-NP	JJ	O	18	NMOD	O
O	O	508	510	or	or	O	CC	O	18	NMOD	O
O	O	511	516	three	three	B-NP	CD	O	18	NMOD	O
O	O	517	524	deleted	delete	I-NP	VBN	O	16	NMOD	O
O	O	525	530	forms	form	I-NP	NNS	O	12	PMOD	O
O	O	531	533	of	of	B-PP	IN	O	18	NMOD	O
T10	B-Entity	534	537	HIV	HIV	B-NP	NN	B-DNA	23	NMOD	B-DNA
T10	I-Entity	537	538	-	-	B-NP	HYPH	I-DNA	23	NMOD	I-DNA
T10	I-Entity	538	539	1	1	I-NP	CD	I-DNA	23	NMOD	I-DNA
T10	I-Entity	540	543	LTR	LTR	I-NP	NN	I-DNA	19	PMOD	I-DNA
O	O	543	544	,	,	O	,	O	26	P	O
O	O	545	547	we	we	B-NP	PRP	O	26	SUB	O
O	O	548	556	obtained	obtain	B-VP	VBD	O	0	ROOT	O
O	O	557	565	evidence	evidence	B-NP	NN	O	26	OBJ	O
O	O	566	570	that	that	B-SBAR	IN	O	27	NMOD	O
O	O	571	574	the	the	B-NP	DT	O	32	NMOD	O
T11	B-Entity	575	581	kappaB	kappaB	I-NP	NN	B-DNA	32	NMOD	B-DNA
T11	I-Entity	582	592	regulatory	regulatory	I-NP	JJ	I-DNA	32	NMOD	I-DNA
T11	I-Entity	593	601	elements	element	I-NP	NNS	I-DNA	38	SUB	I-DNA
O	O	602	609	located	located	B-ADJP	JJ	O	32	NMOD	O
O	O	610	612	in	in	B-PP	IN	O	33	AMOD	O
O	O	613	616	the	the	B-NP	DT	O	37	NMOD	O
T12	B-Entity	617	619	U3	U3	I-NP	NN	B-DNA	37	NMOD	B-DNA
T12	I-Entity	620	626	region	region	I-NP	NN	I-DNA	34	PMOD	I-DNA
O	O	627	630	are	be	B-VP	VBP	O	28	SBAR	O
O	O	631	639	involved	involve	I-VP	VBN	O	38	VC	O
O	O	640	642	in	in	B-PP	IN	O	39	VMOD	O
O	O	643	647	cell	cell	B-NP	NN	O	40	PMOD	O
O	O	647	648	-	-	B-ADVP	HYPH	O	39	P	O
O	O	648	650	to	to	B-PP	TO	O	39	VMOD	O
O	O	650	651	-	-	B-NP	HYPH	O	46	NMOD	O
O	O	651	655	cell	cell	I-NP	NN	O	46	NMOD	O
O	O	656	666	activation	activation	I-NP	NN	O	43	PMOD	O
O	O	667	669	of	of	B-PP	IN	O	46	NMOD	O
T13	B-Entity	670	673	HIV	HIV	B-NP	NN	B-DNA	51	NMOD	B-DNA
T13	I-Entity	673	674	-	-	B-NP	HYPH	I-DNA	51	NMOD	I-DNA
T13	I-Entity	674	675	1	1	I-NP	CD	I-DNA	51	NMOD	I-DNA
T13	I-Entity	676	679	LTR	LTR	I-NP	NN	I-DNA	47	PMOD	I-DNA
O	O	679	680	.	.	O	.	O	26	P	O

O	O	681	685	Cell	Cell	B-NP	NN	O	7	SUB	O
O	O	685	686	-	-	B-ADJP	HYPH	O	1	P	O
O	O	686	688	to	to	B-PP	TO	O	1	NMOD	O
O	O	688	689	-	-	B-NP	HYPH	O	6	NMOD	O
O	O	689	693	cell	cell	I-NP	NN	O	6	NMOD	O
O	O	694	701	contact	contact	I-NP	NN	O	3	PMOD	O
O	O	702	711	activates	activate	B-VP	VBZ	O	0	ROOT	O
O	O	712	714	in	in	B-NP	FW	O	9	AMOD	O
O	O	715	720	vitro	vitro	I-NP	FW	O	10	NMOD	O
O	O	721	728	binding	binding	I-NP	NN	O	31	NMOD	O
O	O	729	731	of	of	B-PP	IN	O	10	NMOD	O
O	O	732	735	the	the	B-NP	DT	O	15	NMOD	O
O	O	736	743	nuclear	nuclear	I-NP	JJ	B-protein	15	NMOD	B-protein
O	O	744	750	factor	factor	I-NP	NN	I-protein	15	NMOD	I-protein
O	O	751	757	kappaB	kappaB	I-NP	NN	I-protein	24	NMOD	I-protein
O	O	758	759	(	(	O	(	O	20	DEP	O
O	O	759	761	NF	NF	B-NP	NN	B-protein	19	NMOD	B-protein
O	O	761	762	-	-	B-NP	HYPH	I-protein	19	P	I-protein
O	O	762	768	kappaB	kappaB	I-NP	NN	I-protein	20	DEP	I-protein
O	O	768	769	)	)	O	)	O	15	NMOD	O
T1	B-Protein	770	773	p50	p50	B-NP	NN	B-protein	24	NMOD	B-protein
O	O	773	774	/	/	B-NP	SYM	O	24	NMOD	O
T2	B-Protein	774	777	p65	p65	I-NP	NN	B-protein	24	NMOD	B-protein
T14	B-Entity	778	789	heterodimer	heterodimer	I-NP	NN	I-protein	11	PMOD	I-protein
O	O	790	792	to	to	B-PP	TO	O	10	NMOD	O
O	O	793	795	an	an	B-NP	DT	O	27	NMOD	O
T15	B-Entity	796	799	HIV	HIV	I-NP	NN	O	25	PMOD	O
T15	I-Entity	799	800	-	-	B-NP	HYPH	O	31	NMOD	O
T15	I-Entity	800	801	1	1	I-NP	CD	O	31	NMOD	O
T15	I-Entity	802	808	kappaB	kappaB	I-NP	NN	O	31	NMOD	O
T15	I-Entity	809	824	oligonucleotide	oligonucleotide	I-NP	NN	O	7	OBJ	O
O	O	824	825	.	.	O	.	O	7	P	O

O	O	826	830	Cell	Cell	B-NP	NN	O	12	SUB	O
O	O	830	831	-	-	B-ADJP	HYPH	O	1	P	O
O	O	831	833	to	to	B-PP	TO	O	1	NMOD	O
O	O	833	834	-	-	B-NP	HYPH	O	3	PMOD	O
O	O	834	838	cell	cell	I-NP	NN	O	7	NMOD	O
O	O	839	846	contact	contact	I-NP	NN	O	7	NMOD	O
O	O	847	857	activation	activation	I-NP	NN	O	4	OBJ	O
O	O	858	860	of	of	B-PP	IN	O	7	NMOD	O
T16	B-Entity	861	863	NF	NF	B-NP	NN	B-protein	11	NMOD	B-protein
T16	I-Entity	863	864	-	-	B-NP	HYPH	I-protein	11	NMOD	I-protein
T16	I-Entity	864	870	kappaB	kappaB	I-NP	NN	I-protein	8	PMOD	I-protein
O	O	871	874	was	be	B-VP	VBD	O	0	ROOT	O
O	O	875	879	only	only	I-VP	RB	O	12	VMOD	O
O	O	880	889	partially	partially	I-VP	RB	O	13	AMOD	O
O	O	890	899	inhibited	inhibit	I-VP	VBN	O	12	VC	O
O	O	900	902	by	by	B-PP	IN	O	15	VMOD	O
O	O	903	906	100	100	B-NP	CD	O	18	AMOD	O
O	O	907	913	microM	microM	I-NP	NN	O	20	NMOD	O
O	O	914	925	pyrrolidine	pyrrolidine	I-NP	NN	O	20	NMOD	O
O	O	926	941	dithiocarbamate	dithiocarbamate	I-NP	NN	O	16	PMOD	O
O	O	942	945	and	and	O	CC	O	12	VMOD	O
O	O	946	949	was	be	B-VP	VBD	O	12	VMOD	O
O	O	950	953	not	not	I-VP	RB	O	22	VMOD	O
O	O	954	964	correlated	correlate	I-VP	VBN	O	22	VC	O
O	O	965	969	with	with	B-PP	IN	O	24	VMOD	O
O	O	970	971	a	a	B-NP	DT	O	28	NMOD	O
O	O	972	983	significant	significant	I-NP	JJ	O	28	NMOD	O
O	O	984	992	decrease	decrease	I-NP	NN	O	25	PMOD	O
O	O	993	995	of	of	B-PP	IN	O	28	NMOD	O
O	O	996	1004	cellular	cellular	B-NP	JJ	B-protein	33	NMOD	B-protein
T3	B-Protein	1005	1014	inhibitor	inhibitor	I-NP	NN	I-protein	33	NMOD	I-protein
T3	I-Protein	1015	1021	kappaB	kappaB	I-NP	NN	I-protein	33	NMOD	I-protein
T3	I-Protein	1022	1027	alpha	alpha	I-NP	NN	I-protein	29	PMOD	I-protein
O	O	1027	1028	.	.	O	.	O	12	P	O

T17	B-Entity	1029	1031	NF	NF	B-NP	NN	B-protein	3	NMOD	B-protein
T17	I-Entity	1031	1032	-	-	I-NP	HYPH	I-protein	3	P	I-protein
T17	I-Entity	1032	1038	kappaB	kappaB	I-NP	NN	I-protein	5	NMOD	I-protein
O	O	1039	1046	nuclear	nuclear	I-NP	JJ	O	5	NMOD	O
O	O	1047	1057	activation	activation	I-NP	NN	O	6	SUB	O
O	O	1058	1061	was	be	B-VP	VBD	O	0	ROOT	O
O	O	1062	1065	not	not	O	RB	O	6	VMOD	O
O	O	1066	1076	detectable	detectable	B-ADJP	JJ	O	6	PRD	O
O	O	1077	1083	before	before	B-PP	IN	O	6	VMOD	O
O	O	1084	1085	1	1	B-NP	CD	O	11	NMOD	O
O	O	1086	1087	h	h	I-NP	NN	O	9	PMOD	O
O	O	1088	1093	after	after	B-PP	IN	O	11	NMOD	O
O	O	1094	1098	cell	cell	B-NP	NN	O	14	NMOD	O
O	O	1099	1106	contact	contact	I-NP	NN	O	12	PMOD	O
O	O	1107	1110	and	and	O	CC	O	6	VMOD	O
O	O	1111	1114	was	be	B-VP	VBD	O	6	VMOD	O
O	O	1115	1124	dependent	dependent	B-ADJP	JJ	O	16	PRD	O
O	O	1125	1127	on	on	B-PP	IN	O	17	AMOD	O
O	O	1128	1135	protein	protein	B-NP	NN	O	20	NMOD	O
O	O	1136	1145	synthesis	synthesis	I-NP	NN	O	18	PMOD	O
O	O	1145	1146	.	.	O	.	O	6	P	O
